Regulus Therapeutics Inc.
RGLS
$7.86
-$0.01-0.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 12.90% | 62.12% | 227.33% | 66.98% | 22.64% |
| Gross Profit | -12.90% | -62.12% | -227.33% | -66.98% | -22.64% |
| SG&A Expenses | 33.49% | 60.58% | 46.49% | 68.92% | 13.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.40% | 65.61% | 87.20% | 67.60% | 19.77% |
| Operating Income | -19.40% | -65.61% | -87.20% | -67.60% | -19.77% |
| Income Before Tax | -13.76% | -58.68% | -79.73% | -57.37% | -18.63% |
| Income Tax Expenses | -- | -- | -- | 0.00% | -- |
| Earnings from Continuing Operations | -13.76% | -58.68% | -79.73% | -57.36% | -18.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.76% | -58.68% | -79.73% | -57.36% | -18.63% |
| EBIT | -19.40% | -65.61% | -87.20% | -67.60% | -19.77% |
| EBITDA | -19.53% | -66.09% | -87.38% | -67.46% | -19.45% |
| EPS Basic | 50.58% | 51.00% | 46.11% | 53.36% | 30.49% |
| Normalized Basic EPS | 50.57% | 50.98% | 46.13% | 53.36% | 30.50% |
| EPS Diluted | 50.58% | 51.00% | 46.11% | 53.36% | 30.49% |
| Normalized Diluted EPS | 50.57% | 50.98% | 46.13% | 53.36% | 30.50% |
| Average Basic Shares Outstanding | 130.20% | 223.90% | 233.55% | 237.48% | 70.66% |
| Average Diluted Shares Outstanding | 130.20% | 223.90% | 233.55% | 237.48% | 70.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |